Why the study?
Clopidogrel response shows wide individual variability linked to CYP2C19 polymorphisms, and clopidogrel resistance relates to adverse outcomes in CAD, but prevalence and effects in Mexican mestizo patients needed evaluation.
Do CYP2C19 polymorphisms predict clopidogrel resistance in Mexican mestizo patients with coronary or cerebral atherosclerosis?
Population
160 CAD and 11 stroke Mexican mestizo patients treated with clopidogrel
Comparison
Unfavorable vs favorable CYP2C19 metabolizer genotypes
Design
Observational study
Key result
Unfavorable CYP2C19 genotypes showed a non-significant trend toward higher clopidogrel resistance compared to favorable genotypes (64.7% vs 39.1%; p=0.059).
Authors
Loading...
CYP2C19 variants may predict clopidogrel response in Mexican mestizos; leaves open whether genotyping improves outcomes in this population.
Observational (n=171)
Do CYP2C19 polymorphisms predict clopidogrel resistance in Mexican mestizo patients with coronary or cerebral atherosclerosis?
Absolute Event Rate: 64.7% vs 39.1%
p-value: p=0.059
In Mexican mestizo patients, CYP2C19 polymorphisms alone do not fully explain in vitro clopidogrel resistance, which appears to be a complex multifactorial phenomenon.
Izaguirre-Ávila et al. (2026) conducted an observational in Coronary artery disease or stroke (n=171). Unfavorable CYP2C19 genotypes (*1/*2, *2/*17, and *2/*2) vs. Favorable CYP2C19 genotypes (*1/*1, *1/*17, and *17/*17) was evaluated on Clopidogrel resistance (p=0.059). Unfavorable CYP2C19 genotypes showed a non-significant trend toward higher clopidogrel resistance compared to favorable genotypes (64.7% vs 39.1%; p=0.059).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: